Skip to main content

Table 1 In vitro comparisons of intermittent versus continuous delivery strategies with different case scenarios at iEPO doses of 50 and 30 ng/kg/min

From: In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients

iEPO dose, ng/kg/min

Cases of IBW

Nominal dose of iEPO in 20 min, mcg

Aerosol deposition of high concentration delivery

Aerosol deposition of low concentration delivery

p

30 mcg/mL

15 mcg/mL

7.5 mcg/mL

Pump rate, mL/h

mcg

%

Pump rate, mL/h

mcg

%

Pump rate, mL/h

mcg

%

50

50 kg

50

5.0

7.8 ± 0.8

15.5 ± 1.6

10.0

9.4 ± 0.4

18.8 ± 0.8

NA

NA

NA

0.050

70 kg

70

7.0

12.2 ± 1.2

17.5 ± 1.7

14.0

10.6 ± 0.6

15.1 ± 0.9

NA

NA

NA

0.127

90 kg

90

9.0

15.0 ± 0.9

16.7 ± 1.0

18.0

13.6 ± 0.8

15.1 ± 0.9

NA

NA

NA

0.127

Overall

70

NA

11.7 ± 3.3

16.6 ± 1.5

NA

11.2 ± 2.0

16.4 ± 2.0

NA

NA

NA

0.691

30

50 kg

30

3.0

6.6 ± 0.6

21.9 ± 2.0

6.0

5.2 ± 0.5

17.5 ± 1.7

12.0

4.1 ± 0.3

13.6 ± 0.8

0.027

70 kg

42

4.2

9.2 ± 1.1

22.0 ± 2.6

8.4

6.6 ± 0.8

15.8 ± 1.9

16.8

4.8 ± 0.5

11.4 ± 1.2

0.027

90 kg

54

5.4

13.5 ± 1.0

25.0 ± 1.8

10.8

9.3 ± 1.8

17.3 ± 3.3

21.6

6.8 ± 0.2

12.6 ± 0.3

0.027

Overall

42

NA

9.8 ± 3.1

23.0 ± 2.4

NA

7.1 ± 2.1

16.9 ± 2.2

NA

5.2 ± 1.3

12.5 ± 1.2

0.003

  1. iEPO inhaled epoprostenol, IBW ideal body weight, NA not available